SG195309A1 - Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders - Google Patents

Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Info

Publication number
SG195309A1
SG195309A1 SG2013089966A SG2013089966A SG195309A1 SG 195309 A1 SG195309 A1 SG 195309A1 SG 2013089966 A SG2013089966 A SG 2013089966A SG 2013089966 A SG2013089966 A SG 2013089966A SG 195309 A1 SG195309 A1 SG 195309A1
Authority
SG
Singapore
Prior art keywords
indazolyl
crystalline form
glucocorticoid receptor
amide derivatives
receptor mediated
Prior art date
Application number
SG2013089966A
Other languages
English (en)
Inventor
Helen Ingemo Andersson
Kelly Yvonne Conway
Michael John Quayle
Original Assignee
Astrazeneca Ab
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Bayer Ip Gmbh filed Critical Astrazeneca Ab
Publication of SG195309A1 publication Critical patent/SG195309A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2013089966A 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders SG195309A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161502656P 2011-06-29 2011-06-29
PCT/GB2012/051503 WO2013001294A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Publications (1)

Publication Number Publication Date
SG195309A1 true SG195309A1 (en) 2013-12-30

Family

ID=46420454

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013089966A SG195309A1 (en) 2011-06-29 2012-06-27 Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders

Country Status (16)

Country Link
EP (1) EP2726464A1 (enExample)
JP (1) JP2014527955A (enExample)
KR (1) KR20140036230A (enExample)
CN (1) CN103814015A (enExample)
AR (1) AR086818A1 (enExample)
AU (1) AU2012277514A1 (enExample)
BR (1) BR112013031759A2 (enExample)
CA (1) CA2839398A1 (enExample)
IN (1) IN2014MN00023A (enExample)
MX (1) MX2013014566A (enExample)
RU (1) RU2013153466A (enExample)
SG (1) SG195309A1 (enExample)
TW (1) TW201305115A (enExample)
UY (1) UY34170A (enExample)
WO (1) WO2013001294A1 (enExample)
ZA (1) ZA201309480B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
CN108314670B (zh) * 2018-02-06 2020-04-07 江苏八巨药业有限公司 一种(s)-2-氯-1-(6-氟-1-苯并二氢吡喃-2-基)-乙醇的制备方法
EP4253396A4 (en) * 2020-11-27 2024-09-11 Mirailab Bioscience Inc. HIGH PURITY BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) AND PROCESS FOR ITS PRODUCTION
CN116283781B (zh) * 2022-12-16 2025-05-13 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代n-苯基吲唑酰胺类化合物、药物组合物和用途
KR102571432B1 (ko) * 2023-02-08 2023-08-29 주식회사 에스씨엘테라퓨틱스 인다졸릴에스테르 및 아미드 유도체를 포함하는 암 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
WO2008079073A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
US20140000601A1 (en) 2010-07-21 2014-01-02 Astrazeneca Ab Inhaler
EP2595683B1 (en) 2010-07-21 2015-03-04 AstraZeneca AB Inhaler

Also Published As

Publication number Publication date
AU2012277514A1 (en) 2014-01-09
BR112013031759A2 (pt) 2016-12-13
KR20140036230A (ko) 2014-03-25
CA2839398A1 (en) 2013-01-03
TW201305115A (zh) 2013-02-01
RU2013153466A (ru) 2015-08-10
IN2014MN00023A (enExample) 2015-06-12
CN103814015A (zh) 2014-05-21
WO2013001294A1 (en) 2013-01-03
JP2014527955A (ja) 2014-10-23
EP2726464A1 (en) 2014-05-07
UY34170A (es) 2013-01-31
AR086818A1 (es) 2014-01-22
ZA201309480B (en) 2015-10-28
MX2013014566A (es) 2014-09-25

Similar Documents

Publication Publication Date Title
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
MX2012013628A (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
SA520411843B1 (ar) Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
GEP20156339B (en) New co-crystals of agomelatine, process for their preparation and pharmaceutical compositions containing them
CL2011001428A1 (es) Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras.
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
MX2013014566A (es) Formas cristalinas de derivados de indozolilamida para el tratamiento de transtornos mediados por el receptor glucocorticoide.
MX2017004852A (es) Inhibidores de aldosterona sintasa.
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
IN2013DN02555A (enExample)
GEP20156332B (en) Pyrazoles as crth2 antagonists
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
MX2014000963A (es) Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide.
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
WO2008130319A3 (en) Novel n-tetrahydronaphtalene or n-chromane carboxamide derivatives for the treatment of pain
UA112981C2 (uk) Варіант людського gdnf
WO2007109141A3 (en) Pharmaceutical compositions for intranasal administration comprising a melatonin receptor agonist, uses thereof